Regeneron Pharmaceuticals (REGN) Assets (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Assets of $41.7 billion for Q2 2026, up 9.19% year-over-year from $38.2 billion in Q2 2025, and up 2.11% quarter-over-quarter from $40.9 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Assets (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Assets history runs 18 years deep, the most recent figure standing at $41.7 billion for Q2 2026.
- In Q2 2026, Assets rose 9.19% year-over-year to $41.7 billion; the TTM figure through Jun 2026 stood at $41.7 billion (up 9.19% YoY), while the FY2025 annual figure was $40.6 billion, up 7.41% from the prior year.
- Assets for Q2 2026 stood at $41.7 billion, up from $40.9 billion in the prior quarter.
- The five-year high for Assets was $41.7 billion in Q2 2026, with the low at $26.3 billion in Q1 2022.
- The 5-year median for Assets is $35.2 billion (2024), against an average of $34.5 billion.
- The sharpest annual moves came in 2022 and 2025: Assets jumped 48.26% in 2022, then climbed 5.91% in 2025.
- Regeneron Pharmaceuticals' Assets stood at $29.2 billion in 2022, then grew by 13.23% to $33.1 billion in 2023, then increased by 14.15% to $37.8 billion in 2024, then advanced by 7.41% to $40.6 billion in 2025, then gained by 2.89% to $41.7 billion in 2026.
- Business Quant data shows REGN's Assets at $41.7 billion in Q2 2026, $40.9 billion in Q1 2026, and $40.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.73 Bn |
| Mar 31, 2026 | 40.87 Bn |
| Dec 31, 2025 | 40.56 Bn |
| Sep 30, 2025 | 40.17 Bn |
| Jun 30, 2025 | 38.22 Bn |
| Mar 31, 2025 | 37.55 Bn |
| Dec 31, 2024 | 37.76 Bn |
| Sep 30, 2024 | 37.44 Bn |
| Jun 30, 2024 | 36.09 Bn |
| Mar 31, 2024 | 34.37 Bn |
| Dec 31, 2023 | 33.08 Bn |
| Sep 30, 2023 | 32.16 Bn |
| Jun 30, 2023 | 30.66 Bn |
| Mar 31, 2023 | 30.06 Bn |
| Dec 31, 2022 | 29.21 Bn |
| Sep 30, 2022 | 27.68 Bn |
| Jun 30, 2022 | 27.21 Bn |
| Mar 31, 2022 | 26.35 Bn |
| Dec 31, 2021 | 25.43 Bn |
| Sep 30, 2021 | 23.67 Bn |